|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Recombx® Ri Autoantibody Test
Test Code92420
CPT Codes
83520<br /> Limited Access Code
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Preferred Specimen
2 mL serum
Minimum Volume
0.5 mL
Other Acceptable Specimens
2 mL CSF collected in a sterile, leak-proof container
Instructions
No informed consent is required.
Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Serum must be separated from cells within 48 hours of collection.
Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Serum must be separated from cells within 48 hours of collection.
Transport Container
Plastic transport vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Fri; Report available: 3-5 days
Reference Range
Serum <1:50
CSF <1:1
CSF <1:1
Clinical Significance
Anti-Ri antibody can be detected in patients with paraneoplastic opsoclonus/myoclonus syndrome. Neoplasms most often associated with anti-Ri include breast cancer, small cell lung cancer, and gynecological cancers. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.